Cas9 Stable Cell Line - CHO-K1

The CHO-K1 cell line, derived from Chinese hamster ovary cells, is a cornerstone of biomedical research and biopharmaceutical production. Renowned for its robust growth in suspension culture, high protein expression, and adaptability to serum-free culture conditions, the CHO-K1 cell line is ideal for recombinant protein therapies such as monoclonal antibodies. The Cas9 Stable Cell Line - CHO-K1 is constructed by directly integrating CRISPR-Cas9 technology into the CHO-K1 genome. This engineered cell line stably expresses the Cas9 endonuclease, eliminating the need for repeated transfection with Cas9 plasmids. Its key advantages include reduced experimental variability, stable gene editing efficiency during passage, and compatibility with complex genomic manipulations.

The Cas9 Stable Cell Line - CHO-K1 holds transformative potential in drug discovery and biomanufacturing. It enables high-throughput functional genomics screening, allowing for the rapid knockout or knock-in of genes involved in apoptosis, metabolism, or cell signaling pathways, thereby identifying novel drug targets. In biopharmaceutical development, researchers have used this cell line to genetically engineer the CHO-K1 host to enhance its productivity, such as by knocking out genes that trigger apoptosis under bioreactor stress or by inserting therapeutic cassettes at genomically safe sites. This precision reduces cloning screening time from months to weeks. Furthermore, this cell line is crucial for constructing disease models (e.g., introducing oncogenic mutations) and optimizing the glycosylation profile of biologics by editing glycosyltransferase genes. Its stability ensures the consistent performance of CRISPR in GMP-compliant large-scale manufacturing, making it an indispensable tool for developing next-generation cell therapies and biosimilars.